Imatron's 1995 results drop

Article

Ultrafast CT developer Imatron last week reported a $2.4 millionnet loss and sharply lower revenues for 1995 (end-December), butstruck an optimistic stance due to promising clinical resultsbeing reported on its technology. The South San Francisco,

Ultrafast CT developer Imatron last week reported a $2.4 millionnet loss and sharply lower revenues for 1995 (end-December), butstruck an optimistic stance due to promising clinical resultsbeing reported on its technology. The South San Francisco, CA,vendor said that the lower results were due to increased expensesrelated to the start-up of its HeartScan Imaging subsidiary, aswell as delays in securing orders in the Far East.

Imatron reported revenues for the year of $26.7 million, downfrom $33.6 million in 1994. The company's $2.4 million net lossfor 1995 compares with net income of $2.3 million in 1994.

For the fourth quarter, Imatron posted a net loss of $2.2 millionon revenues of $7 million, compared with net income of $700,000on sales of $10.8 million in the fourth quarter of 1994.

Imatron said the loss was attributable to expenses relatedto the building of a national network of HeartScan Imaging centers,which will provide coronary artery disease (CAD) screening directlyto the public, using Imatron's ultrafast CT scanners. Imatronopened centers in Houston and Seattle last year and laid the groundworkfor new centers in Washington, DC, and Pittsburgh.

Scanner sales were negatively affected by problems securingletters of credit from foreign banks. Two orders to China havebeen delayed, and others put on hold, Imatron said.

On the positive side, the company has been receiving mediaattention based on clinical reports of the utility of its technologyin detecting early signs of CAD (SCAN3/13/96). Imatron believesthat these studies will lay the foundation for increased consumerdemand for ultrafast CT CAD screening to be provided by HeartScancenters.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.